

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE {Plastic box of 10 /50 doses}**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Eurican DHPPi lyophilisate for suspension for injection.

**2. STATEMENT OF ACTIVE SUBSTANCES**

1 dose contains:

Attenuated distemper virus .....	10 <sup>4.0-6.0</sup>	CCID <sub>50</sub>
Attenuated canine adenovirus type 2 .....	10 <sup>2.5-6.3</sup>	CCID <sub>50</sub>
Attenuated canine parvovirus type 2 .....	10 <sup>4.9-7.1</sup>	CCID <sub>50</sub>
Attenuated canine parainfluenza type 2 virus .....	10 <sup>4.7-7.1</sup>	CCID <sub>50</sub>

**3. PACKAGE SIZE**

10 doses: 10x1 dose lyophilisate.

50 doses: 50x1 dose lyophiliste.

**4. TARGET SPECIES**

Dogs

**5. INDICATIONS**

**6. ROUTES OF ADMINISTRATION**

Subcutaneous use.

**7. WITHDRAWAL PERIODS**

**8. EXPIRY DATE**

Exp. {mm/yyyy}

Once reconstituted use immediately.

**9. SPECIAL STORAGE PRECAUTIONS**

Store and transport refrigerated.

Do not freeze.

Protect from light.

**10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read the package leaflet before use.

**11. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**13. NAME OF THE MARKETING AUTHORISATION HOLDER**

Boehringer Ingelheim Vetmedica GmbH

**14. MARKETING AUTHORISATION NUMBER**

Vm 61700/3053

**15. BATCH NUMBER**

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS {  
Lyophilisate vial: 1 dose}**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Eurican DHPPi



**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

DHPPi

1 d.

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}

## **PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:**

### **PACKAGE LEAFLET**

#### **1. Name of the veterinary medicinal product**

Eurican DHPPi lyophilisate for suspension for injection.

#### **2. Composition**

One dose of lyophilisate contains:

##### **Active substances:**

	<b>Minimum</b>	<b>Maximum</b>
Attenuated canine distemper virus, strain BA5	10 <sup>4.0</sup> CCID <sub>50</sub> *	10 <sup>6.0</sup> CCID <sub>50</sub> *
Attenuated canine adenovirus type 2, strain DK13	10 <sup>2.5</sup> CCID <sub>50</sub> *	10 <sup>6.3</sup> CCID <sub>50</sub> *
Attenuated canine parvovirus type 2, strain CAG2	10 <sup>4.9</sup> CCID <sub>50</sub> *	10 <sup>7.1</sup> CCID <sub>50</sub> *
Attenuated canine parainfluenza virus type 2, strain CGF 2004/75	10 <sup>4.7</sup> CCID <sub>50</sub> *	10 <sup>7.1</sup> CCID <sub>50</sub> *

(\* CCID<sub>50</sub>: 50% cell culture infective dose)

#### **3. Target species**

Dogs.

#### **4. Indications for use**

Active immunisation of dogs to:

- Prevent mortality and clinical signs caused by canine distemper virus (CDV),
- Prevent mortality and clinical signs caused by infectious canine hepatitis virus (CAV-1),
- Reduce viral excretion during respiratory disease caused by canine adenovirus type 2 (CAV-2),
- Prevent mortality, clinical signs and viral excretion caused by canine parvovirus (CPV)\*,
- Reduce viral excretion caused by canine parainfluenza virus type 2 (CPiV).

Onset of immunity: 2 weeks after the second injection of the primary vaccination course for all strains.

Duration of immunity: at least one year after the second injection of the primary vaccination course for all strains.

Current available challenge and serological data show that protection for distemper virus, adenovirus and parvovirus\* lasts for 2 years after primary vaccination course followed by a first annual booster. Any decision to adapt the vaccination schedule of this veterinary medicinal product needs to be made on a case by case basis, taking into account the vaccination history of the dog and the epidemiological context.

\*Protection has been demonstrated against canine parvovirus type 2a, 2b and 2c either by challenge (type 2b) or serology (type 2a and 2c).

## **5. Contraindications**

None.

## **6. Special warnings**

### Special warnings:

Vaccinate healthy animals only.

### Special precautions for safe use in the target species:

Apply usual aseptic procedures.

After vaccination, the live CAV-2 and CPV vaccine strains can transiently be shed without adverse consequence for in-contact animals.

### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

### Pregnancy:

Can be used during pregnancy.

### Interaction with other medicinal products and other forms of interaction:

Safety and efficacy data are available which demonstrate that this vaccine can be administered with Eurican LR, Eurican L, Eurican Lmulti or Eurican L4 vaccines (used as solvent) where available.

Safety and efficacy data are available which demonstrate that this vaccine can be administered on the same day but not mixed with Rabisin if the vaccine has been reconstituted with Eurican L, Eurican Lmulti or Eurican L4.

When administered with Boehringer Ingelheim's vaccines containing rabies, the minimum age for vaccination is 12 weeks of age.

When administered reconstituted with the Eurican LR vaccine a small and transient nodule (maximum size 1.5 cm) at the injection site may be induced due to the presence of aluminium hydroxide and a slight swelling (~4 cm) may occur after the injection at injection site, regressing generally within 1-4 days.

When mixed with the Eurican L4 vaccine a swelling (less than 6 cm) may very commonly occur at the injection site, disappearing within 8 days, anorexia may commonly occur and vocalisation, tachycardia and tachypnoea may uncommonly be observed. For Eurican L4, no safety data in pregnant bitches are available for the additional inactivated strain, *Leptospira Australis*.

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

Overdose:

No adverse reactions other than those mentioned in section ‘adverse reactions’ were observed after administration of a 10-fold overdose of the lyophilisate.

Major incompatibilities:

Do not mix with any other veterinary medicinal product, except the compatible vaccines (Eurican LR, Eurican L, Eurican Lmulti or Eurican L4) mentioned in section 3.8 above.

**7. Adverse events**

Dogs:

Common (1 to 10 animals / 100 animals treated):	Injection site swelling <sup>1</sup> , injection site pruritus, injection site pain. Lethargy <sup>2</sup> . Emesis <sup>2</sup> .
Uncommon (1 to 10 animals / 1,000 animals treated):	Anorexia, polydipsia, hyperthermia. Diarrhoea. Muscle tremor. Muscle weakness. Injection site warmth, injection site lesions <sup>3</sup> .
Rare (1 to 10 animals / 10,000 animals treated):	Hypersensitivity reaction (facial oedema, anaphylactic shock, urticaria) <sup>4</sup> .

<sup>1</sup> Slight ( $\leq 2$  cm), immediately after injection. It usually regresses within 1-6 days.

<sup>2</sup> Transient.

<sup>3</sup> Cutaneous.

<sup>4</sup> Some of which are life-threatening. Appropriate symptomatic treatment should promptly be provided.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or via your national reporting system at:

Website: <https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine>

e-mail: [adverse.events@vmd.gov.uk](mailto:adverse.events@vmd.gov.uk)

## **8. Dosage for each species, routes and method of administration**

After reconstitution, inject a 1-ml dose subcutaneously according to the following schedule:

### **Primary vaccination:**

Two injections separated by an interval of 4 weeks from 7 weeks of age.

When administered with Boehringer Ingelheim's vaccines containing rabies, the minimum age for vaccination is 12 weeks of age.

In cases where high levels of maternally derived antibodies are suspected by the veterinarian and the primary vaccination course was completed before 16 weeks of age, a third injection using a Boehringer Ingelheim vaccine containing Distemper, Adenovirus and Parvovirus is recommended from 16 weeks of age, at least 3 weeks after the second injection.

**Revaccination:** Administer one dose 12 months after completion of the primary vaccination course. Dogs should be revaccinated with a single booster dose on an annual basis.

## **9. Advice on correct administration**

Aseptically reconstitute the contents of the lyophilizate with a compatible Boehringer Ingelheim vaccine (Eurican LR, Eurican L, Eurican Lmulti or Eurican L4) where available. Shake well before use. The entire contents of the reconstituted vial should be administered as a single dose. The reconstituted contents shall be an opalescent yellow to orange suspension.

## **10. Withdrawal periods**

Not applicable.

## **11. Special storage precautions**

Keep out of the sight and reach of children.  
Store and transport refrigerated (2 °C – 8 °C).  
Do not freeze.  
Protect from light.

Do not use this veterinary medicinal product after the expiry date which is stated on the label after Exp. The expiry date refers to the last day of that month.

Shelf life after reconstitution according to directions: use immediately.

## **12. Special precautions for disposal**

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

## **13. Classification of veterinary medicinal products**

Veterinary medicinal product subject to prescription

## **14. MARKETING AUTHORISATION NUMBERS AND PACK SIZES**

Vm 61700/3053

Plastic box of 10 vials (glass) of lyophilisate (1 dose).

Plastic box of 50 vials (glass) of lyophilisate (1 dose).

Not all pack sizes may be marketed.

## **15. PID LINK (Do not print heading)**

*[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]*

Find more product information by searching for the 'Product Information Database' on [www.gov.uk](http://www.gov.uk).

## **16. Contact details**

### Marketing authorisation holder

Boehringer Ingelheim Vetmedica GmbH  
Binger Strasse 173  
55216 Ingelheim am Rhein  
Germany

### Manufacturer responsible for batch release:

Boehringer Ingelheim Animal Health France SCS,  
Laboratoire Porte des Alpes  
Rue de l'Aviation  
69800 Saint-Priest  
France

**17. Other information**

POM-V

*Gavin Hall*  
Approved: 21 August 2025